Loading institutional data...
Loading institutional data...
Held by 551 of 5,944 reporting institutions (97th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $72.00 today, the market must believe free cash flow compounds 19.2%/yr for a decade (off $236M normalized FCF).
The market's 19.2% is more optimistic than its 9-yr track record.
2-stage DCF · 0.15B shares · net debt -$162M
mean 11.9% · volatility σ 35% · implied rate exceeded in 1/9 yrs
Central path = implied 19.2%/yr growth; shaded band = ±1σ (35%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| TECH | $11.2B | 156.5× | 51.8× | 9.2× | 5.2% | 64.8% | 6.0% | 3.8% | 3.8% | — | 551 |
Peers = companies sharing TECH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 20% of free cash flow, leaving room to grow it and fund buybacks. Last year: $50M dividends + $276M buybacks = $326M returned on $257M FCF.
1 consecutive years of dividend increases · -14%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 4%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-08-05
No material risks flagged.
Where each multiple sits in its own 14-yr range · 91th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 32.8 | 33.7 | 34.6 | 32.0 | 31.6 | 32.3 | 33.6 | 35.2 |
| Gross Profit | 67.2 | 66.3 | 65.4 | 68.0 | 68.4 | 67.7 | 66.4 | 64.8 |
| SG&A | 37.4 | 37.0 | 35.3 | 34.9 | 33.7 | 33.3 | 40.2 | 48.3 |
| Operating Income | 21.2 | 20.5 | 21.3 | 25.5 | 26.8 | 26.3 | 17.8 | 8.4 |
| Income Tax | -0.0 | 2.2 | 6.4 | 0.9 | 3.5 | 4.7 | 1.5 | 2.1 |
| Net Income | 19.6 | 13.5 | 31.0 | 15.1 | 24.6 | 25.1 | 14.5 | 6.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on TECH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B 100.0% | $1.16B 100.0% | $1.14B 100.0% | $1.11B 100.0% | $931.0M 100.0% | $738.7M 100.0% | $714.0M 100.0% | $643.0M 100.0% | $563.0M 100.0% | $499.0M 100.0% |
| Cost of Revenue | $429.4M 35.2% | $389.3M 33.6% | $366.9M 32.3% | $349.1M 31.6% | $298.2M 32.0% | $255.5M 34.6% | $240.5M 33.7% | $210.8M 32.8% | $188.5M 33.5% | $162.4M 32.5% |
| Gross Profit | $790.3M 64.8% | $769.7M 66.4% | $769.8M 67.7% | $756.5M 68.4% | $632.9M 68.0% | $483.2M 65.4% | $473.5M 66.3% | $432.1M 67.2% | $374.5M 66.5% | $336.7M 67.5% |
| Selling, General & Admin | $588.5M 48.3% | $466.4M 40.2% | $378.4M 33.3% | $372.8M 33.7% | $325.0M 34.9% | $260.6M 35.3% | $264.4M 37.0% | $240.6M 37.4% | $200.4M 35.6% | $140.9M 28.2% |
| Total Operating Expenses | $688.0M 56.4% | $563.0M 48.6% | $470.9M 41.4% | $459.9M 41.6% | $395.6M 42.5% | $325.8M 44.1% | $326.8M 45.8% | $296.0M 46.0% | $254.0M 45.1% | $186.1M 37.3% |
| Operating Income | $102.3M 8.4% | $206.7M 17.8% | $298.9M 26.3% | $296.6M 26.8% | $237.3M 25.5% | $157.4M 21.3% | $146.7M 20.5% | $136.2M 21.2% | $120.6M 21.4% | $150.6M 30.2% |
| Interest Expense | $8.5M 0.7% | $15.7M 1.4% | $11.2M 1.0% | $11.3M 1.0% | $14.0M 1.5% | $19.2M 2.6% | $21.7M 3.0% | $10.2M 1.6% | $7.4M 1.3% | $1.7M 0.4% |
| Other Income (Expense), net | -$3.8M -0.3% | -$21.0M -1.8% | $39.7M 3.5% | $4.8M 0.4% | -$89.1M -9.6% | $119.1M 16.1% | -$34.7M -4.9% | -$10.2M -1.6% | -$8.6M -1.5% | -$3.1M -0.6% |
| Pretax Income | $98.5M 8.1% | $185.7M 16.0% | $338.7M 29.8% | $301.4M 27.3% | $148.2M 15.9% | $276.5M 37.4% | $112.0M 15.7% | $126.0M 19.6% | $112.0M 19.9% | $147.5M 29.6% |
| Income Tax Expense | $25.1M 2.1% | $17.6M 1.5% | $53.2M 4.7% | $38.3M 3.5% | $8.6M 0.9% | $47.2M 6.4% | $15.9M 2.2% | -$198K -0.0% | $35.9M 6.4% | $43.0M 8.6% |
| Net Income | $73.4M 6.0% | $168.1M 14.5% | $285.3M 25.1% | $272.1M 24.6% | $140.4M 15.1% | $229.3M 31.0% | $96.1M 13.5% | $126.2M 19.6% | $76.1M 13.5% | $104.5M 20.9% |
| Per Share | ||||||||||
| EPS (Basic) | $0.47 | $1.07 | $1.81 | $1.73 | $0.91 | $6.00 | $2.54 | $3.36 | $2.04 | $2.81 |
| EPS (Diluted) | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $5.82 | $2.47 | $3.31 | $2.03 | $2.80 |
| Weighted Avg Shares (Basic) | 157.5M | 157.7M | 157.2M | 156.9M | 155.0M | 38.2M | 37.8M | 37.5M | 37.3M | 37.2M |
| Weighted Avg Shares (Diluted) | 159.7M | 160.8M | 161.9M | 164.1M | 161.9M | 39.4M | 38.9M | 38.1M | 37.5M | 37.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.